Skip to main content
Clinical Ophthalmology (Auckland, N.Z.) logoLink to Clinical Ophthalmology (Auckland, N.Z.)
. 2026 Nov 6;20:645505. doi: 10.2147/OPTH.S645505

Patient-Reported Outcomes After Glaucoma Surgery: A Narrative Review for Clinical Decision-Making

Songxin Yang 1,*, Rui Zhang 1,*, Xianming Ouyang 1, Li Li 1, Gang Lin 1, Lin Xiao 1, Mei Yang 1, Shunkun Pan 2,✉, Kunpeng Pang 3,✉
PMCID: PMC13751908  PMID: 43016837

Abstract

Purpose

To synthesize evidence on patient-reported outcomes (PROs), including vision-related quality of life, after glaucoma surgery and to organize this evidence into a clinically oriented framework for selecting, interpreting, and applying these outcomes across procedures, with particular attention to evidence gaps in angle-closure glaucoma, Asian populations, and combined cataract–angle surgery.

Methods

This narrative review considered studies involving adults undergoing trabeculectomy, glaucoma drainage device implantation, minimally invasive glaucoma surgery, lens-based surgery, or combined cataract–angle procedures, together with studies evaluating PRO instruments used in glaucoma. We searched PubMed, Embase, and the Cochrane Library for English-language studies published from January 2000 through July 7, 2026, while retaining seminal earlier articles. We prioritized randomized controlled trials, prospective cohorts, registries, and studies of instrument development and measurement properties. Studies were selected for clinical relevance and synthesized qualitatively without a formal risk-of-bias assessment.

Results

We identified three main instrument families: disease-specific questionnaires, generic and preference-based utility measures, and adaptive item banks. Across procedures, patient-reported benefits appeared to be more consistently associated with reduced medication and symptom burden and avoidance of surgical morbidity than with the magnitude of intraocular pressure reduction. Comparative evidence suggested broadly similar vision-related quality of life after trabeculectomy and glaucoma drainage device implantation. Benefits reported after minimally invasive procedures were often accompanied by reductions in medication burden, whereas direct PRO evidence for combined cataract–angle procedures remained very limited. Evidence was particularly sparse for angle-closure glaucoma and Asian populations, as well as for PRO responsiveness in surgical settings and thresholds for meaningful change.

Conclusion

PROs provide clinically relevant information beyond intraocular pressure and medication counts, but their interpretation is limited by instrument heterogeneity, uncertain responsiveness, and limited evidence on minimal important differences. A standardized, surgery-relevant core set of PRO measures, validated across glaucoma subtypes and populations, could improve cross-procedure comparison, preoperative counseling, and shared decision-making.

Keywords: patient-reported outcomes, glaucoma surgery, vision-related quality of life, shared decision-making, angle-closure glaucoma

Introduction

Glaucoma is the leading cause of irreversible blindness worldwide, and its burden is still rising. The number of affected adults aged 40 to 80 years is projected to reach about 111.8 million by 2040, driven largely by population aging.1 When topical medication and laser therapy fail to halt progressive optic-nerve damage, incisional surgery becomes central to preserving sight. Over the past three decades the surgical repertoire has widened well beyond trabeculectomy. Trabeculectomy remains the reference procedure and provides substantial intraocular pressure reduction, although at the cost of bleb-related morbidity. Other options include aqueous drainage devices for refractory or high-risk eyes, a growing range of minimally invasive glaucoma surgery (MIGS) procedures that generally offer a safer profile and faster recovery, although with more modest pressure reduction, and combined cataract–angle procedures that treat the lens and the conventional outflow pathway in one operation.2–5 Each option sits at a different point on the efficacy–safety spectrum, and the choice among them has become correspondingly individualized. Despite this expansion, surgical success remains defined largely by clinician-centered outcomes: intraocular pressure reduction, medication use, and anatomic or visual-field outcomes. These measures remain essential but do not fully capture postoperative symptoms, daily visual function, or treatment burden.

Pressure control does not, by itself, capture what patients actually experience. It does not directly capture the symptom burden of surgery and chronic topical therapy, the inconvenience and ocular-surface effects of lifelong medication, limitations in reading, mobility, and driving, or the psychological burden of a potentially blinding diagnosis. Patient-reported outcomes (PROs) and vision-related quality of life (VRQoL) are now widely accepted as important complementary endpoints for judging the value of glaucoma surgery.6 Major surgical trials have embedded quality-of-life assessment accordingly,2,3,7,8 and pivotal device trials have begun to report VRQoL alongside pressure outcomes.9 A growing range of instruments is now available, from the NEI VFQ-25 and the GQL-15 to the surgery-oriented Glaucoma Outcomes Survey. The evidence base that has emerged is nonetheless fragmented. Instruments differ markedly in content and measurement properties, and only a minority meet rigorous development standards;10 head-to-head PRO comparisons between procedures are scarce; the minimal important difference is rarely established; and the link between disease progression and patient-perceived disability remains incompletely mapped.11 Most evidence, moreover, comes from primary open-angle glaucoma in Western populations, leaving angle-closure disease and Asian populations underrepresented even though together they carry a large share of the global glaucoma burden.12 Clinicians therefore lack an integrated and clinically applicable synthesis of how glaucoma surgery affects patient experience in addition to conventional clinical outcomes.

This narrative review addresses a practical clinical question: how should PROs be selected, interpreted, and incorporated into clinical decision-making after glaucoma surgery? We organize the evidence around three linked issues: the selection of appropriate PRO instruments, procedure-specific PRO evidence, and the clinical and psychosocial factors that influence postoperative PROs and shared decision-making. The review differs from earlier instrument-focused or single-procedure reviews in three respects. First, it synthesizes evidence across the full surgical spectrum rather than a single technique. Second, it focuses on the understudied areas of angle-closure glaucoma, Asian populations, and combined cataract–angle surgery, where the mismatch between clinical activity and patient-centered evidence is particularly evident. Third, it considers how PRO evidence can inform preoperative counseling and individualized surgical choice rather than treating PROs solely as research endpoints. The recent development and validation of surgery-specific measures,13,14 together with a growing call to standardize PRO assessment in glaucoma surgery,15 make such a synthesis both timely and clinically relevant.

Literature Search Methods

We used PubMed, Embase, and the Cochrane Library to identify relevant studies. We searched these databases using subject headings (Medical Subject Headings [MeSH] and Emtree) together with title and abstract keywords to identify studies reporting PROs or VRQoL after glaucoma surgery (Box 1). The search was restricted to English-language articles published from January 2000 to July 7, 2026; seminal pre-2000 articles were retained when they defined a core PRO instrument or provided essential epidemiologic background. This language restriction may have excluded PRO and instrument-validation studies published in non-English-language journals, particularly those involving Asian populations and patients with angle-closure glaucoma, a limitation discussed below. Retrieved records were screened by title and abstract, followed by full-text review. Priority was given to randomized controlled trials, prospective cohorts, registries, and studies of instrument development or measurement properties; case reports and conference abstracts were excluded. The reference lists of retrieved articles and relevant reviews were hand-searched to identify additional sources. Regional databases such as CNKI, Wanfang, and Japan Medical Abstracts and grey literature were not systematically searched, and no formal systematic citation-chasing strategy was applied. The scope was confined to adults with glaucoma; congenital and childhood glaucoma, which differ in surgical approach and in the instruments required to assess PROs, were not addressed. Consistent with the aims of a narrative review, studies were selected for clinical relevance and synthesized qualitatively. No formal methodological quality or risk-of-bias assessment was performed.

Box 1.

Literature search terms

  • Glaucoma surgery terms: trabeculectomy; glaucoma drainage device; tube shunt; minimally invasive glaucoma surgery; MIGS; goniotomy; goniosynechialysis; canaloplasty; trabecular bypass; combined cataract–angle surgery; phacoemulsification.

  • Patient-reported outcome terms: patient-reported outcome; patient-reported outcome measure; PROM; quality of life; vision-related quality of life; VRQoL; health utility; patient satisfaction; symptom burden; questionnaire; GQL-15; Glaucoma Symptom Scale; NEI VFQ-25.

The two term groups were combined using the Boolean operator AND; database-specific MeSH and Emtree terms were applied as appropriate.

Conceptual Framework: Patient-Reported Outcomes, Vision-Related Quality of Life, and Health Utility

The terminology of patient-centered measurement is sometimes used inconsistently, although its terms describe distinct concepts that determine what a study measures and how its findings should be interpreted. A patient-reported outcome (PRO) is any report of a patient’s health condition that comes directly from the patient, without interpretation of that response by a clinician or anyone else, a definition set out in regulatory guidance and widely adopted in ophthalmic research.6 The instrument used to elicit and quantify such a report is a patient-reported outcome measure (PROM). A PRO is the outcome reported by the patient, whereas a PROM is the instrument used to measure it.16 This distinction has practical implications. Conflating the two may imply that all questionnaires measure the same construct. In fact, PROMs differ in the construct they target, the scale on which they express it, and the conceptual framework that supports their content. The sections that follow define the constructs used in this review, from symptom experience and vision-related quality of life to preference-based health utility, and outline the criteria used to evaluate a PROM (Figure 1).

Figure 1.

Two-part flow diagram of glaucoma patient-reported outcomes constructs and a clinical decision pathway. A) Vertical construct gradient from disease-proximal at the top to disease-agnostic at the bottom. Four stacked sections list constructs and example instruments. Symptom experience, GSS. Vision-related quality of life, GQL-15 and NEI VFQ-25. Generic HRQoL, SF-6D. Preference-based health utility, EQ-5D and Glaucoma Utility Index, leading by an arrow to QALY. B) Clinical decision pathway shown as four stacked steps connected by downward arrows. Step 1, Select an instrument, with the subtext, Match the construct, purpose and disease stage. Step 2, Stratify the procedure evidence, followed by five labeled items: Trabeculectomy; Glaucoma drainage device; MIGS; Combined cataract-angle surgery; Lens extraction (angle closure). Step 3, Weigh the determinants, with three labeled items: Disease-related; Treatment-related; Psychosocial / functional. Step 4, Shared decision-making at the bedside.

A clinical decision framework for patient-reported outcomes in glaucoma surgery. The schematic integrates (A) the construct gradient, from symptom experience to vision-related quality of life, generic health-related quality of life, and preference-based health utility, with (B) the clinical decision pathway of this review: selecting an instrument, stratifying procedure-specific evidence, weighing determinants, and translating patient-reported outcomes into shared decision-making.

Abbreviations: EQ-5D, EuroQol 5-Dimension; GQL-15, Glaucoma Quality of Life-15; GSS, Glaucoma Symptom Scale; HRQoL, health-related quality of life; MIGS, minimally invasive glaucoma surgery; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; QALY, quality-adjusted life-year; SF-6D, Short Form 6-Dimension.

A PRO is defined by its source rather than its subject matter, which distinguishes it from the clinician- and instrument-derived outcomes that have traditionally defined surgical success. Intraocular pressure, mean deviation, and cup-to-disc ratio are clinician- or instrument-derived measurements that describe ocular status; a PRO records the patient’s own account of symptoms, functioning, and well-being, and can be obtained only from the person who experiences them. Between these categories lie observer-reported and performance-based outcomes, such as a proxy’s report or a timed reading or mobility task, which provide information about functioning without originating from the patient’s own perception. This taxonomy matters in glaucoma because conventional clinical endpoints, however essential to managing the disease, do not directly assess symptoms, daily functioning, or well-being. They also do not directly represent the burden of chronic therapy, the fear that accompanies a potentially blinding diagnosis, or the functional cost of peripheral visual-field loss.17 PROs therefore provide a distinct source of evidence that complements clinician- and instrument-derived outcomes.6,18

PROs encompass several distinct constructs, ranging from disease-specific symptoms to generic health utility. The construct of interest should be defined before an instrument is selected. Symptom measures capture ocular-surface complaints, glare, and the discomfort of topical therapy or of a filtering bleb, but provide limited information about broader functioning. VRQoL captures how impaired visual function affects reading, mobility, driving, dependency, and the emotional consequences of sight loss. Generic health-related quality of life captures broader physical, mental, and social functioning and allows comparison across different conditions. Health utility provides a single preference-weighted index that supports cross-condition comparison and the calculation of quality-adjusted life-years for economic evaluation. Each construct answers a different question: what the patient feels, how the patient functions, and how the patient’s health state is valued relative to other health states. A measure that captures one does not, in general, capture the rest. Apparent disagreement between PROMs applied to the same patient may therefore reflect differences in the constructs measured rather than measurement error.

The credibility of a PROM rests on an explicit conceptual framework that links every item to the construct it claims to measure, and on demonstrable involvement of patients in defining that content, rather than on the surface plausibility of its questions. Regulatory and methodological standards converge on this requirement. Such guidance emphasizes documented content validity—the extent to which an instrument adequately reflects the construct in the intended population and context of use—as the foundation for evaluating other measurement properties.6,10 The COSMIN taxonomy further considers structural validity, reliability, and responsiveness.10 Many questionnaires in common use antedate these standards and were developed without a clearly articulated conceptual model or meaningful patient input, a deficiency shown to be widespread in the glaucoma literature.10 These principles inform the selection of an appropriate instrument and the interpretation of procedure-specific evidence, particularly when studies use measures that assess different constructs. They also highlight the absence of an agreed, patient-informed core set of PRO measures for glaucoma surgery, which has been identified as a prerequisite for cumulative and comparable evidence.15

Instruments for Measuring Patient-Reported Outcomes in Glaucoma

In glaucoma, how a patient-reported outcome is measured matters as much as which outcome one sets out to measure. The available instruments are not interchangeable: they differ in the constructs they assess, their mode of administration, and the rigor of their validation. Three broad approaches are in common use. Disease- and vision-specific questionnaires assess symptoms and vision-related functioning. Generic measures assess broader health status, whereas preference-based measures generate utility values that support cross-disease comparison and economic evaluation. Modern item banks, often administered by computerized adaptive testing (CAT), aim to combine precision with low respondent burden. No single instrument serves every purpose. The appropriate choice depends on the purpose of measurement, disease stage, and the evidence supporting the instrument. An instrument that distinguishes among patients may not be sufficiently responsive to detect change after surgery or suitable for valuing health states in cost-utility analysis. The evidence behind these tools is also uneven, and a systematic COSMIN-based appraisal has shown that only a minority of the many available questionnaires meet rigorous standards of development and validation.10,19 The sections that follow review each approach, the responsiveness of available instruments, and the practical matching of an instrument to the surgical question (Table 1).

Table 1.

Principal Patient-Reported Outcome Instruments in Glaucoma

Instrument Items (n) Construct Measured Measurement-Property Evidence Recommended Use
NEI VFQ-2520 25 Vision-specific function and socioemotional well-being (Rasch analysis indicates two distinct constructs)21,22 Among the few with adequate support;10 better read as two subscales Default vision-related quality-of-life endpoint in surgery; a minimal important difference is available in a surgical population3
GQL-1523 15 Field-loss visual disability (glare, dark adaptation, peripheral awareness, mobility) Adequate; discriminates across severity;24 suboptimal targeting led to reengineering Glaucoma-specific functional disability
GAL-925 9 Glaucoma activity limitation (unidimensional Rasch-refined GQL-15) Psychometrically superior to GQL-15 Brief activity-limitation assessment
Glau-QoL 3626 36 Glaucoma-specific health-related quality of life (anxiety, self-image, treatment burden domains) Discriminates across disease stages (developer report) Multidomain HRQoL including treatment burden
GSS27 10 Symptom burden (ocular and non-ocular, medication-related) Among the few with adequate support10 Symptom and medication burden; postoperative symptoms
VAQ28 33 Vision-related activity limitation Used mainly in research (adopted in CIGTS) Vision-related activity limitation (research-oriented)
GlauCAT item banks29–31 Item bank (several hundred candidate items; administered by CAT) Broad glaucoma quality-of-life domains (item-response theory) Modern psychometrics; calibrated in Asian cohorts; high precision reached with ≈3.7 (moderate) to 7.3 (advanced) items per domain (Asian version ≈12.1/15.7)32,33 Efficient, precise routine capture
Glaucoma Outcomes Survey13,14 42 (function 27, symptom 7, psychological 7, satisfaction 1) Surgery-oriented (MIGS) quality of life Internal consistency 0.75–0.93; test–retest ICC 0.83–0.92 (developer report) Evaluating glaucoma surgery, especially MIGS
SF-36/SF-6D34 36/6 dimensions Generic health profile; SF-6D yields a preference-based utility Ceiling effects; low sensitivity to vision35,36 Generic comparison and economic analysis
EQ-5D37 5 dimensions Generic preference-based utility Ceiling effects; low sensitivity to vision35,36 Cost-utility/QALY estimation; utility ≈0.90, falling to ≈0.83 once both eyes are impaired
Glaucoma Utility Index38 Discrete-choice-derived index Glaucoma-specific preference-based utility Anchored to glaucoma-relevant health states Cost-utility analysis with disease relevance
VFQ-UI39 Vision-anchored index Vision-specific utility Acknowledged limits in targeting and precision Vision-specific utility
TSS-IOP40/Glausat41/EDSQ42/GTCAT43 Varies Satisfaction with, and adherence to, ocular hypotensive therapy Satisfaction- and adherence-specific instruments Pre- vs postoperative medication burden and satisfaction

Notes: Instruments listed are representative, not exhaustive; systematic appraisals catalog many more.10,19,44–46

Abbreviations: CAT, computerized adaptive testing; CIGTS, Collaborative Initial Glaucoma Treatment Study; EDSQ, Eye-Drop Satisfaction Questionnaire; EQ-5D, EuroQol 5-Dimension; GAL-9, Glaucoma Activity Limitation-9; GlauCAT, glaucoma computerized adaptive test; GQL-15, Glaucoma Quality of Life-15; GSS, Glaucoma Symptom Scale; GTCAT, Glaucoma Treatment Compliance Assessment Tool; HRQoL, health-related quality of life; ICC, intraclass correlation coefficient; MIGS, minimally invasive glaucoma surgery; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; QALY, quality-adjusted life-year; SF-36/SF-6D, 36-item Short-Form Health Survey/Short-Form 6-Dimension; TSS-IOP, Treatment Satisfaction Survey for Intraocular Pressure; VAQ, Visual Activities Questionnaire; VFQ-UI, Visual Function Questionnaire Utility Index.

Disease-specific instruments remain central to glaucoma PRO research because they target the visual functions and symptoms most affected by the disease and its treatment. The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) is the most widely used vision-specific measure. It assesses general vision, near and distance activities, peripheral and color vision, ocular pain, driving, dependency, and the social and emotional effects of visual loss.20 Although it was developed for eye disease in general rather than for glaucoma alone, it is widely used in surgical studies and was the primary quality-of-life outcome in the Tube vs Trabeculectomy trial.3 The 15-item Glaucoma Quality of Life-15 (GQL-15) was developed specifically for glaucoma and focuses on disability associated with visual-field loss, including glare, dark adaptation, peripheral awareness, and outdoor mobility. It correlates moderately with objective measures such as mean deviation,23 and later validation confirmed that it discriminates across disease severity and between participants with and without glaucoma.24 The 36-item Glau-QoL, developed from in-depth patient interviews, includes explicit domains for anxiety, self-image, and treatment burden and assesses quality of life across disease stages.26 Broader vision-specific activity inventories, such as the Visual Activities Questionnaire, have also been used in glaucoma populations, notably in the Collaborative Initial Glaucoma Treatment Study.28 The Rasch-scaled Impact of Vision Impairment questionnaire provides an interval-level, vision-specific measure that has been applied across eye diseases, including glaucoma.47 The 10-item Glaucoma Symptom Scale (GSS) focuses on symptoms rather than visual function. It captures the symptom burden that patients attribute to glaucoma and topical therapy, including ocular complaints such as burning, tearing, and foreign-body sensation, as well as non-ocular symptoms.27 This makes it particularly relevant to surgery, which may reduce medication-related complaints while introducing new symptoms such as bleb dysesthesia. These instruments assess different constructs; symptom, functional, and overall quality-of-life scores should not be treated as interchangeable. Conflating them obscures which dimension of patient experience has changed and limits comparison across surgical studies. Comprehensive catalogs of available glaucoma instruments and their measurement properties are provided in recent systematic and scoping reviews.44–46

The credibility of any PRO score depends on its measurement properties, and psychometric evaluation has identified important limitations in several commonly used glaucoma instruments. Rasch analysis has repeatedly shown that the NEI VFQ-25 may not function as a single interval-scaled measure. It combines two distinct constructs—visual functioning and socioemotional well-being—raising concerns about the use of a single composite score and supporting separate assessment of these domains.21,22 A similar analysis of the GQL-15 found suboptimal targeting and precision and led to the development of a shorter, more coherent nine-item scale, the Glaucoma Activity Limitation-9 (GAL-9).25 A COSMIN-based systematic review found that the GQL-15, GSS, and NEI VFQ-25 had the strongest supporting evidence, whereas many instruments lacked a clearly stated conceptual framework or meaningful patient involvement.10 These limitations have encouraged the development of glaucoma-specific item banks. One program used patient interviews and expert consensus to assemble several hundred candidate items spanning multiple quality-of-life domains, allowing the resulting bank to be administered through CAT rather than as a fixed questionnaire.29 Because the CAT algorithm selects the most informative items for each respondent, it can retain much of the precision of the full item bank while requiring fewer questions.32,33 Item banks calibrated in Asian cohorts have broadened this work beyond predominantly Western samples,30,31 and a pilot program in a hospital glaucoma clinic demonstrated the feasibility of integrating adaptive PRO assessment into routine care.48 The Glaucoma Outcomes Survey is especially relevant to surgical evaluation. It was developed through focus groups and cognitive interviews13 and subsequently field-tested across several centers; its developers reported acceptable internal consistency and test–retest reliability for assessing minimally invasive glaucoma surgery.14 It begins to address the limited availability of PROMs developed specifically for glaucoma surgery.

Generic and preference-based measures serve different purposes. Generic profile instruments assess broad physical and mental health, whereas preference-based instruments summarize health as a utility value for cross-disease comparison and economic evaluation. Generic profile instruments such as the SF-36 capture broad physical and mental health, and scores may decline in advanced glaucoma, but they are not vision-specific.34 Utility values derived from the EQ-5D decline with increasing glaucoma severity and binocular visual loss; population-based estimates show a decrease from near-normal values to substantially lower utilities once both eyes are impaired, providing inputs for cost-utility modeling.37 The main limitation of generic preference-based measures is their limited sensitivity to vision-specific change. Instruments such as the EQ-5D and SF-6D show ceiling effects and may be less responsive to visual change than time-trade-off methods, such that a clinically important visual decline may produce little change in the measured utility.35,36 This limitation occurs across ocular diseases and may understate the value of sight-preserving surgery.49 To retain economic comparability while improving disease relevance, glaucoma-specific preference-based measures have been developed. The Glaucoma Utility Index, derived from a discrete-choice experiment, produces utility values that decline with disease severity and remain anchored to health states important to patients.38 The vision-derived VFQ Utility Index has also been evaluated, although limitations in targeting and precision remain.39 Such endpoints support health-economic evaluations in landmark trials, including the quality-adjusted life-year gains reported for early lens extraction in primary angle-closure glaucoma2 and the EQ-5D-based evaluation that supported selective laser trabeculoplasty as a cost-effective first-line alternative to medication.7

An instrument that distinguishes patients well does not necessarily detect change within an individual patient; this distinction between discriminative validity and longitudinal responsiveness is critical in surgical evaluation. The central surgical question is whether an operation improves how a patient sees and feels over time. Responsiveness has been studied less extensively than reliability or construct validity in glaucoma, but longitudinal evidence indicates that faster visual-field progression is associated with measurable declines in NEI VFQ-25 scores, suggesting that a vision-specific instrument can capture clinically relevant deterioration over time.11 Interpretation also requires a threshold for meaningful change. A change in score is difficult to judge without a minimal important difference, and such thresholds remain scarce in the surgical literature. The Tube vs Trabeculectomy trial estimated an important difference for the NEI VFQ-25 in a surgical population, providing a rare interpretive anchor.3 Where such thresholds are unavailable, statistical significance alone cannot establish patient-important benefit. This limitation reduces the clinical interpretability and comparability of surgical PRO findings.

Another group of instruments assesses treatment satisfaction and adherence burden rather than visual function. This domain is relevant to surgery because reducing the demands of chronic topical therapy is often an important treatment objective. Satisfaction measures such as the Treatment Satisfaction Survey for Intraocular Pressure and the glaucoma-specific Glausat assess how patients evaluate the effectiveness, side effects, and convenience of pressure-lowering treatment.40,41 The Eye-Drop Satisfaction Questionnaire links satisfaction to adherence,42 whereas the Glaucoma Treatment Compliance Assessment Tool evaluates the beliefs and barriers that influence medication use.43 These instruments are relevant to surgical studies because some patient-reported improvement after surgery may reflect reduced medication burden. Measuring that burden directly before and after surgery complements functional and utility endpoints.

Because each instrument type answers a different question, the choice of a PRO instrument for glaucoma surgery should follow from the purpose of measurement rather than from habit. For cross-sectional discrimination, an instrument must distinguish among patients; for evaluation of surgical change, documented responsiveness and a defined minimal important difference are required. Few instruments have both properties clearly established in surgical settings, with the NEI VFQ-25 providing one of the best-supported examples.3 Disease stage adds a further constraint. Instruments prone to ceiling effects in early disease may miss improvements after surgery, whereas floor effects in advanced disease may obscure meaningful residual function. The clinical or research question also points toward particular tools. For symptom and medication burden, the GSS or an ocular-surface symptom measure may be appropriate; for global vision-related quality of life, the NEI VFQ-25 or a GlauCAT-based assessment may be preferable; and for economic evaluation, a preference-based utility measure or the Glaucoma Utility Index is required (Table 2). No single PRO should automatically serve as the sole primary endpoint of a surgical trial, because current instruments may lack sufficient sensitivity, particularly for slowly evolving disease modification.50 Combining a disease-specific functional measure with a symptom or utility measure may provide a broader assessment of surgical benefit than any single questionnaire.

Table 2.

Selecting a Patient-Reported Outcome Instrument by Clinical Question

Clinical Question Recommended Instrument(s) Practical Default Rationale Administration Access/Licensing Language/Mode Responsiveness/MID Caveat
Symptom or medication burden GSS;27 an ocular-surface symptom measure GSS Directly captures symptoms and medication-related discomfort Brief (~5 min) Verify current access and permission terms Widely translated; self-administered Not interchangeable with functional scales
Global vision-related quality of life NEI VFQ-25;20 a GlauCAT-based assessment32,33 NEI VFQ-25 Covers function plus socioemotional impact; CAT is efficient ~10 min (VFQ-25); shorter with CAT Verify current access and permission terms Multiple languages; self- or interviewer-administered VFQ-25 best read as two subscales21,22
Value for money/cost-utility EQ-5D;37 Glaucoma Utility Index38 EQ-5D Produces QALYs for economic evaluation Brief Registration required; licensing terms vary by use Extensively translated; self-administered Generic measures are relatively insensitive to vision35,36
Longitudinal change after surgery An instrument with documented responsiveness, at present chiefly NEI VFQ-253 NEI VFQ-25 Requires responsiveness and a defined minimal important difference ~10 min Verify current access and permission terms Multiple languages; self- or interviewer-administered A minimal important difference is undefined for most instruments in the surgical setting3,50

Notes: Pairing a disease-specific functional measure with a symptom or utility instrument usually captures surgical benefit more faithfully than any single questionnaire. No instrument should serve as the sole primary endpoint of a surgical trial.50

Abbreviations: CAT, computerized adaptive testing; EQ-5D, EuroQol 5-Dimension; GlauCAT, glaucoma computerized adaptive test; GSS, Glaucoma Symptom Scale; MID, minimal important difference; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; QALY, quality-adjusted life-year.

Taken together, the instrument landscape has expanded from fixed-length questionnaires to psychometrically stronger item banks and a measure developed specifically for surgical evaluation. Important gaps nevertheless remain. Few instruments have been formally validated for responsiveness after glaucoma surgery, and minimal important differences are rarely available, making it difficult to determine whether statistically significant changes are clinically meaningful. Their applicability to angle-closure glaucoma and Asian populations also remains under-tested, despite recent item-bank development in Asian cohorts.31 Priorities include a standardized core set of surgery-relevant PRO measures, empirically defined thresholds for meaningful change, and validation across glaucoma subtypes and populations. Until these are available, cross-procedure comparisons will remain limited by nonuniform and incompletely interpretable measurement.

Patient-Reported Outcomes by Surgical Procedure

Glaucoma operations differ in mechanism, invasiveness, and the balance between pressure-lowering efficacy and surgical risk. These differences may produce distinct profiles of patient-reported benefit and burden. Surgery may preserve visual function and reduce medication-related symptoms and adherence burden, but it may also introduce complications, new ocular-surface or bleb-related symptoms, and a period of visual recovery. The available evidence is summarized by procedure in Table 3. Direct head-to-head PRO comparisons remain scarce, follow-up is often short, and instrument heterogeneity limits cross-study comparison. Current evidence is therefore informative but not definitive.

Table 3.

Patient-Reported Evidence by Glaucoma Procedure and Population

Procedure Key Studies Instrument(s) Principal Patient-Reported Finding Benefit–Burden Profile Population (Subtype; Region) Overall Evidence Profile
Trabeculectomy [4,51–53] Utility, VRQoL, satisfaction Transient decline in the first postoperative month, recovering toward baseline by the third; bleb-related discomfort a recognized reason for reoperation Powerful pressure lowering; bleb-related morbidity POAG; Western Moderate
Canaloplasty (bleb-sparing comparator) [54] Satisfaction Higher satisfaction, less postoperative burden, and fewer reoperations than trabeculectomy despite more modest pressure control Lower morbidity; less pressure lowering POAG; Western Moderate
Glaucoma drainage device [3,55,56] NEI VFQ-25 No clinically significant VRQoL difference vs trabeculectomy (Tube vs Trabeculectomy); device-versus-device comparisons report pressure/complications rather than PROs Option for refractory/high-risk eyes; more invasive POAG; Western Moderate (few head-to-head PRO data)
Minimally invasive glaucoma surgery [15,57–60] GSS, OSDI, VRQoL Greater likelihood of medication-free control; better ocular-surface and VRQoL metrics; symptom scores comparable to trabeculectomy and correlated with medication count Safety and rapid recovery; weaker pressure lowering POAG; Western Low–moderate (inconsistent endpoints)
Combined cataract–angle surgery [5,9,61–65] NEI VFQ-25, OSDI, satisfaction Greater VFQ-25/OSDI improvement than cataract surgery alone through 2 years; sustained medication reduction and higher satisfaction (HORIZON: medication 1.7→0.3 vs 1.7→0.7; ≥20% IOP reduction 77.3% vs 57.8%; iStent inject VFQ-25/OSDI responder rate 58.0% vs 45.8%) Convergence of several benefit sources; low burden POAG (mostly); Western Low–moderate
Lens extraction in angle-closure [2,66–68] EQ-5D Better EQ-5D health status and greater QALY gains than laser iridotomy (EAGLE: EQ-5D gain +0.052, 95% CI 0.015–0.088; ICER £14,284/QALY) Mechanism-directed treatment PACG; mixed/Asian (sparse) Strong for early lens extraction; limited for other lens-based or combined procedures
Combined cataract–angle surgery in Asian PACG [69] GQL-15, GSS In 31 eyes over 12 months: improved GQL-15 (36.3→29.1) and GSS (71.2→77.6) with lower IOP (27.2→16.0 mmHg), reduced medication (2.55→0.06), improved acuity (logMAR 1.14→0.65), 12-month success 0.742; patient-reported gains showed no stable correlation with concurrent IOP, acuity, or medication change Potential multidomain benefit; small-sample evidence PACG; Asian Very limited (single-center retrospective)

Notes: Evidence for angle-closure glaucoma and Asian populations remains limited, particularly for combined cataract–angle procedures. The overall evidence profile represents a qualitative narrative judgment based on study design, the amount and consistency of available evidence, the directness of comparisons, and the relevance of the reported patient-reported outcomes. It is not a formal GRADE assessment or risk-of-bias rating.

Abbreviations: CI, confidence interval; EQ-5D, EuroQol 5-Dimension; GQL-15, Glaucoma Quality of Life-15; GSS, Glaucoma Symptom Scale; HORIZON, Schlemm canal microstent pivotal trial; ICER, incremental cost-effectiveness ratio; IOP, intraocular pressure; logMAR, logarithm of the minimum angle of resolution; OSDI, Ocular Surface Disease Index; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; PRO, patient-reported outcome; QALY, quality-adjusted life-year; VFQ-25, 25-item Visual Function Questionnaire; VRQoL, vision-related quality of life.

Trabeculectomy remains the long-standing reference filtering procedure and can achieve substantial reductions in intraocular pressure and medication use. These effects may reduce the ocular-surface and adherence burden of chronic topical therapy.51 However, the filtering bleb may cause dysesthesia, tearing, and irritation, and bleb-related complications may require additional surgery.52 Prospective studies show that vision-related quality of life and utility may decline during the first postoperative month and recover toward baseline by the third month, indicating that the timing of assessment and the occurrence of complications influence observed PROs.4,53 Canaloplasty, a nonpenetrating alternative that avoids a filtering bleb, has been associated with higher satisfaction, lower postoperative burden, and fewer reoperations than trabeculectomy despite more modest pressure control.54 Overall, patient experience after trabeculectomy appears to reflect the balance between reduced medication burden and bleb-related morbidity rather than pressure reduction alone.

Aqueous drainage devices are generally reserved for refractory or high-risk eyes. The Tube vs Trabeculectomy trial provides the strongest direct comparative PRO evidence in this setting. Using the NEI VFQ-25, it found no clinically significant difference in vision-related quality of life between Baerveldt tube implantation and trabeculectomy with mitomycin C, suggesting broadly similar patient-reported trajectories.3 The trial also estimated an important difference for the NEI VFQ-25 in a surgical population, providing one of the few available interpretive anchors for postoperative score changes. Comparisons among drainage devices have largely focused on pressure and complication endpoints, as illustrated by the Ahmed Baerveldt Comparison study55 and the Ahmed vs Baerveldt study.56 The patient-reported consequences of selecting one device rather than another therefore remain insufficiently characterized. Current evidence does not support assuming a patient-reported advantage for a particular drainage device or for drainage-device surgery over trabeculectomy. Counseling should instead reflect the clinical indication, expected recovery, and complication burden.

Minimally invasive glaucoma surgery aims to reduce surgical morbidity and recovery time, but rigorous PRO evidence has not kept pace with its clinical adoption. Available studies most consistently associate patient-reported improvement with reduced medication burden. Controlled trials indicate that several MIGS procedures increase the likelihood of medication-free control compared with cataract surgery alone,57 and reduced reliance on topical therapy is associated with better ocular-surface metrics and vision-related quality of life after MIGS combined with cataract extraction.58 When a subconjunctival gel stent was compared with trabeculectomy, Glaucoma Symptom Scale scores were similar, and symptom burden correlated with the number of topical medications required.59 A randomized comparison of the PreserFlo MicroShunt with trabeculectomy found fewer early postoperative interventions but somewhat lower surgical success; like most device trials, it reported pressure and surgical success rather than patient-reported endpoints.60 Current evidence therefore supports medication burden as an important correlate of patient experience, but direct procedure-specific PRO comparisons remain limited and the instruments used are heterogeneous. These limitations support standardized surgical assessment with measures such as the Glaucoma Outcomes Survey.15

Combined cataract and angle surgery warrants particular attention because lens extraction itself can improve vision-related quality of life, whereas the added angle procedure may further reduce intraocular pressure and medication burden. Randomized evidence from a trabecular micro-bypass device implanted with cataract surgery showed greater improvement in NEI VFQ-25 and ocular-surface disease index responses than cataract surgery alone through two years.9 A Schlemm canal microstent combined with phacoemulsification produced substantial and sustained medication reduction.5,61 After phacoemulsification with a gel stent, medication reduction was accompanied by improved symptom scores and greater satisfaction.62 Observational cohorts suggest that combined cataract–MIGS does not worsen and may improve vision-related quality of life relative to cataract surgery alone,63,64 and real-world series have reported high levels of quality-of-life improvement and satisfaction across several angle-based devices.65 A systematic synthesis has also documented the additional pressure and medication benefit of adding MIGS to cataract surgery.70 However, because cataract extraction itself improves vision-related quality of life, the independent patient-reported contribution of the added angle procedure remains difficult to isolate. Early lens extraction in primary angle-closure glaucoma has produced quality-adjusted life-year gains compared with laser iridotomy.2 Combined procedures may therefore provide both visual and treatment-burden benefits, but direct attribution of PRO improvement to the angle component requires further study. The role of lens-based and combined surgery in angle-closure disease, together with evidence from Asian populations, is considered in the following section.

Comparative and registry studies suggest that glaucoma interventions may yield similar overall PROs despite differing clinical profiles. The Collaborative Initial Glaucoma Treatment Study randomized newly diagnosed patients to initial medical or surgical treatment and found broadly similar overall quality of life between groups, although local ocular symptoms were more frequent in the surgical group.71 The Treatment of Advanced Glaucoma Study extended this comparison to advanced disease; over five years, NEI VFQ-25–measured vision-related quality of life was similar between primary trabeculectomy and primary medical treatment, despite lower pressure and less visual-field progression with surgery.72 The Registry in Glaucoma Outcomes Research likewise found no clinically relevant differences in Glaucoma Symptom Scale or NEI VFQ scores across medical, laser, and incisional strategies, although the surgical group had the greatest improvement in visual acuity.73,74 Selective laser trabeculoplasty also produced quality-of-life outcomes at least equivalent to medication while reducing costs and the need for eye drops.7 Taken together, these studies indicate that intervention choice often involves different patterns of clinical benefit, symptoms, and treatment burden rather than a consistently superior patient-reported outcome. This distinction should be made explicit during patient counseling.

Across procedures, PROs appear to be more consistently associated with relief of medication and symptom burden and avoidance of new surgical morbidity than with the magnitude of intraocular pressure reduction alone. Combined cataract–angle surgery may provide both visual and treatment-burden benefits, but the independent contribution of the angle procedure remains difficult to determine. These conclusions are narrative inferences drawn from heterogeneous studies rather than directly tested causal relationships. They remain limited by the scarcity of direct PRO comparisons, short and inconsistent follow-up, instrument heterogeneity, and the limited availability of data in angle-closure glaucoma and non-Western populations. They should therefore not be interpreted as evidence of causal superiority for any individual procedure. These limitations frame the sections that follow.

Angle-Closure Glaucoma and Asian Populations: An Understudied Priority for Patient-Reported Research

Most evidence on PROs after glaucoma surgery derives from primary open-angle glaucoma and Western populations, whereas primary angle-closure glaucoma contributes substantially to the global glaucoma burden, particularly in East and South Asia.1,12,75 Available comparative evidence does not establish that controlled angle-closure glaucoma is associated with greater impairment in vision-related quality of life than controlled open-angle glaucoma. Its separate consideration is instead justified by two features. First, the crystalline lens is central to both the disease mechanism and its treatment, making lens-based surgery particularly relevant. Second, the populations with the greatest disease burden remain underrepresented in PRO studies, instrument validation, and estimates of meaningful change. This mismatch between clinical burden and patient-centered evidence makes angle-closure glaucoma and Asian populations a priority for further study.

Vision-Related Quality of Life in Angle-Closure vs Open-Angle Glaucoma

Among patients with well-controlled disease, a direct comparison using the NEI VFQ-25 found that most domains of vision-related quality of life were broadly similar between primary angle-closure and primary open-angle glaucoma, with only modest differences.12 Because this comparison was cross-sectional and focused on chronically controlled eyes, it may not capture the acute symptoms and psychological effects of an angle-closure attack. Within primary angle-closure glaucoma, established visual-field dysfunction is associated with substantially lower NEI VFQ-25 scores, and the decrement increases with the severity of field loss.76 Utility values in Chinese patients with angle-closure and open-angle glaucoma likewise fall within a similar range, reflecting the shared effect of advancing disease.77 Population-based Asian data also associate glaucoma, including angle-closure disease, with poorer visual function, vision-related quality of life, and health utility than in unaffected individuals.78 Taken together, the limited evidence suggests that steady-state quality of life is more closely related to functional damage than to the angle-closure mechanism alone.

Lens-Based and Combined Surgery in Angle-Closure Disease

In angle-closure disease, the crystalline lens is an important anatomical contributor and therapeutic target. The landmark randomized comparison of early clear-lens extraction with laser peripheral iridotomy in primary angle closure with raised intraocular pressure or established primary angle-closure glaucoma showed better health status on the EQ-5D, greater quality-adjusted life-year gains, and less need for subsequent pressure-lowering treatment after lens extraction.2 An accompanying economic evaluation found early lens extraction to be cost-effective over plausible time horizons.66 These findings provide strong patient-centered and economic support for lens extraction in appropriately selected angle-closure disease, but they should not be interpreted as evidence for the additional value of an angle procedure. When cataract coexists with angle-closure glaucoma, phacoemulsification may be performed alone or combined with another glaucoma procedure. Studies comparing phacoemulsification alone with phacoemulsification and trabeculectomy have reported broadly similar visual-acuity and pressure outcomes but different complication profiles,67 whereas phacoemulsification with goniosynechialysis has been evaluated as a less invasive option in refractory angle-closure disease.68 However, PROs have rarely been reported in these studies. The favorable utility evidence for lens extraction therefore cannot be assumed to apply equally to all combined procedures, and the independent patient-reported contribution of the additional glaucoma component remains uncertain.

Asian Populations and the Evidence Gap

The populations most affected by angle-closure disease remain underrepresented in PRO research. Because instruments and interpretive thresholds developed largely in Western open-angle glaucoma cohorts may not transfer directly, population-specific validation is needed. Glaucoma-specific item banks and computerized adaptive tests have been developed and psychometrically evaluated in Asian cohorts, broadening rigorous PRO assessment beyond predominantly Western samples.31 A small retrospective study of 31 eyes with primary angle-closure glaucoma and coexisting cataract reported 12-month improvements in the Glaucoma Quality of Life-15 and Glaucoma Symptom Scale after phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy, alongside lower intraocular pressure, reduced medication burden, and improved visual acuity.69 Changes in PRO scores did not show consistent correlations with concurrent changes in intraocular pressure, visual acuity, or medication count. Given the small retrospective sample, this finding should be considered hypothesis-generating rather than evidence that patient-reported and conventional clinical outcomes are independent. Overall, PRO evidence for combined surgery in Asian populations with angle-closure glaucoma remains limited, and the relevant instruments, interpretive thresholds, and procedure-specific outcomes require further validation.

Angle-closure glaucoma and Asian populations remain underrepresented in patient-centered surgical research despite their substantial disease burden. Available evidence suggests that steady-state quality of life is more closely associated with functional loss than with the angle-closure mechanism alone, and randomized data support lens extraction as a patient-centered and cost-effective intervention in appropriately selected angle-closure disease. Evidence on PROs after combined cataract and glaucoma procedures is considerably less developed, particularly in Asian populations. Priorities include validated disease- and population-specific instruments, empirically derived minimal important differences, population-specific normative PRO data, and prospective comparative studies that distinguish the contribution of lens extraction from that of the additional glaucoma procedure.

Determinants of Patient-Reported Outcomes After Surgery

Patient-reported improvement after glaucoma surgery is influenced by factors beyond postoperative intraocular pressure, and understanding these determinants is essential for interpreting procedure-specific evidence and counseling patients realistically. Three broad classes of factors shape the result: disease-related factors, chiefly the extent, laterality, and progression of visual-field loss; treatment-related factors, principally the burden of topical medication and its effect on the ocular surface, together with surgical complications; and psychosocial and functional factors, including mood, illness understanding, and the downstream consequences for mobility and driving (Table 4). Because these factors may operate partly independently of intraocular pressure, an operation that meets anatomical or pressure-based criteria may not improve the patient’s experience, whereas one that provides only modest pressure reduction may nonetheless improve daily life.

Table 4.

Determinants of Patient-Reported Outcomes After Glaucoma Surgery

Domain Determinant Direction on Patient-Reported Outcome Modifiability Key Evidence
Disease-related Extent of binocular visual-field loss Greater loss → lower PRO Non-modifiable [79,80]
Location of loss (central/inferior) Central and inferior loss are associated with greater functional impact Non-modifiable [81,82]
Better-eye severity Advanced damage in the better eye → lower PRO Non-modifiable [83,84]
Rate of progression Faster progression → steeper PRO decline Partly (treatment slows progression) [11]
Treatment-related Medication and ocular-surface burden Greater burden → lower PRO Modifiable (surgery reduces medication) [85–88]
Treatment burden (adherence, dosing, cost, visits) Greater burden → lower PRO Modifiable [89]
Surgical/bleb morbidity New symptoms → lower PRO Modifiable (procedure choice) [52]
Psychosocial/functional Depression/anxiety Present → lower PRO Modifiable [90,91]
Illness understanding Better understanding → higher PRO Modifiable (education) [92]
Falls and fear of falling Present → lower PRO Modifiable (rehabilitation) [93–96]
Driving Impairment → lower PRO Partly [97,98]

Notes: Generic utility measures may be less sensitive to these gradations than vision-specific instruments, so the apparent strength of a determinant depends partly on the instrument selected.99 The modifiability column highlights preoperative and perioperative intervention targets.

Abbreviation: PRO, patient-reported outcome.

The dominant disease-related determinant of vision-related quality of life is the amount and distribution of visual-field loss, particularly in the better-seeing eye. Cross-sectional studies consistently show that worse binocular field status corresponds to lower scores across most domains of vision-specific questionnaires,79 and this association is evident even in mild-to-moderate disease, indicating that quality of life may begin to decline earlier than is often assumed.80 Longitudinal data provide stronger evidence of a temporal association: faster visual-field progression is accompanied by steeper declines in quality-of-life scores,11 and the location of progression also matters, with central and inferior loss exerting the greatest impact.81,82 Severity in the better eye is especially influential, with substantial impairment emerging once that eye sustains advanced damage.83,84 Notably, generic utility measures may be less sensitive to these gradations than vision-specific instruments, so the apparent strength of the severity–quality-of-life relationship depends partly on the instrument chosen.99 The determinant and the tool used to measure it therefore cannot be considered in isolation. Treatment-related factors are among the factors most directly modifiable by surgery. Chronic topical therapy imposes a substantial burden through ocular-surface disease: a large proportion of medicated patients report ocular-surface symptoms, and both prevalence and severity rise with the number of agents used and with preservative exposure,85–87 a pattern confirmed across multiple international centers.88 Beyond the ocular surface, the cumulative demands of adherence, dosing, cost, and clinic attendance constitute a treatment burden that patients describe as independent of the disease itself and as a distinct detractor from quality of life.89 These observations are consistent with a recurring theme from the procedure-specific evidence: patient-reported benefit after surgery may be associated with reduced medication burden and its ocular-surface consequences rather than with pressure reduction alone. Conversely, surgical complications and new symptoms such as bleb dysesthesia may act in the opposite direction, so the net treatment-related effect reflects the balance between treatment burden relieved and surgical morbidity introduced.

Psychosocial and functional factors are frequently underappreciated in surgical evaluation despite their strong association with patient-reported outcomes. Depression and anxiety occur more often in patients with glaucoma than in comparison groups and correlate with poorer quality-of-life scores,90,91 while a patient’s understanding of the disease is associated with lower psychological distress and higher quality of life, suggesting that disease understanding may be a modifiable factor.92 The functional consequences of field loss are equally salient: inferior visual-field loss is associated with an increased rate of falls,93 fear of falling and consequent activity restriction rise with severity,94,95 and this fear can mediate reductions in activity and further falls.96 Driving, a domain patients prize highly, is likewise affected, with glaucoma and binocular field loss associated with impaired performance and a higher risk of at-fault motor-vehicle collisions.97,98 These outcomes matter because they represent the functional and psychosocial consequences that glaucoma treatment ultimately aims to prevent or limit, and because several, including fear of falling, illness understanding, and mood, may be amenable to intervention alongside surgical care.

The determinants of post-surgical patient-reported outcomes are therefore multidimensional, and conventional clinical metrics capture only part of this variation. Two practical implications follow. First, patient-reported benefit cannot be inferred reliably from intraocular pressure or anatomical success alone; surgical outcomes should be interpreted in relation to the disease-related, treatment-related, and psychosocial factors that affect symptoms and functioning. Second, several of these determinants may be modifiable, making perioperative care an opportunity not only to lower pressure but also to reduce medication burden, address ocular-surface disease, and support psychological and functional adaptation. However, how these determinants interact and how their relative influence changes after surgery remain poorly defined, because much of the available evidence derives from cross-sectional studies or medically treated cohorts. This limitation should be considered when translating PRO evidence into shared decision-making.

Translating Patient-Reported Outcomes into Shared Decision-Making and Practice

The purpose of measuring patient-reported outcomes after glaucoma surgery extends beyond expanding the research evidence base; it is to improve the decisions patients and clinicians make together and the care that follows. Translation occurs in three settings. In the consultation, PRO evidence informs how surgeons counsel patients about what an operation is likely to change in daily life and helps align procedure selection with individual patient priorities. In routine practice, patient-reported outcome measures (PROMs) can be captured longitudinally to monitor the individual patient rather than the study cohort. In health policy, preference-based outcomes inform economic evaluations that may influence which procedures are funded and recommended. Each setting continues to develop and remains constrained by the measurement and evidence limitations described earlier.

Aligning surgery with patient preferences requires knowing what patients actually value, and a growing body of stated-preference research shows that these values are heterogeneous and may not align with clinicians’ priorities. Discrete-choice experiments demonstrate that patients weigh treatment efficacy, the risks and burdens of therapy, symptom relief, and the continuity and expertise of care, trading among these attributes in ways that vary between individuals.100–102 A systematic synthesis confirms that outcome-related attributes generally dominate but that process and burden attributes carry meaningful weight,103 and preference work focused on minimally invasive devices has begun to identify the benefits and risks patients regard as decisive.104 Patient preferences can guide care only when incorporated into shared decision-making, a process shaped by patient, clinician, and health-system factors.105 In practice, that process often falls short: preoperative understanding of glaucoma surgery can be limited,106,107 and patients describe wanting fuller information and a more equal partnership than they receive.107 Explicit management of expectations, grounded in evidence about what surgery is and is not likely to achieve, is therefore an important clinical application of PRO research. Patient priorities should be elicited before procedure selection rather than after a decision has already been made (Box 2).

Box 2.

Practical points for using patient-reported outcomes after glaucoma surgery

  • Do not judge surgical success by intraocular-pressure reduction alone.

  • Match the instrument to the clinical question: visual function, symptom burden, treatment satisfaction, or health utility.

  • Use glaucoma-specific instruments when the aim is to capture disease-related visual disability.

  • Weigh ocular-surface symptoms and medication burden when interpreting postoperative patient-reported outcomes.

  • In angle-closure glaucoma with cataract, interpret patient-reported improvement in relation to both lens extraction and the angle-based intervention.

  • Where a threshold for meaningful change is undefined, report the direction and magnitude of change and avoid relying on statistical significance alone.

  • Incorporate patient-reported findings into preoperative counseling and shared decision-making.

Embedding PROMs in routine glaucoma care is the second setting, and current evidence shows a gap between feasibility and widespread adoption. Surveyed ophthalmic professionals generally regard PROMs as useful for communication, monitoring, and decision-making, yet report limited experience and cite practical obstacles, including the time required and uncertainty about interpreting scores.108 Implementation studies indicate that clinical integration is feasible: a patient-reported outcome and experience measure has been incorporated into an Australian glaucoma practice to capture understanding, treatment acceptability, and visual concerns,109 and the computerized adaptive testing systems discussed earlier have been deployed within clinic workflow.48 An important barrier to interpretation is the scarcity of established thresholds for meaningful change, which makes it difficult to determine whether a change in an individual patient’s score warrants clinical action. The estimation of an important difference for the NEI VFQ-25 in a surgical trial illustrates both the value and the current rarity of such anchors.3

The third setting is health-economic evaluation, in which preference-based outcomes are particularly important because utility values are used to estimate the quality-adjusted life-years that underpin cost-utility analysis and inform funding decisions. Glaucoma-specific and generic utility instruments have informed evaluations of several surgical and interventional strategies. Selective laser trabeculoplasty was shown to be cost-effective relative to medication using an EQ-5D-based outcome;7 primary surgical management was evaluated against medical therapy in advanced disease;110 and trabecular bypass devices were assessed for cost-utility against usual care.111 Modeling studies extend such analyses to settings and subtypes where trial data are sparse.112 The evidence base nevertheless remains limited: a systematic review of minimally invasive surgery and laser trabeculoplasty found that, although clinical outcomes were widely reported, humanistic and economic data remained comparatively scarce.113,114 Consequently, many economic evaluations rely on utility estimates extrapolated from other populations or derived from generic instruments with limited sensitivity to vision-specific change.

Across all three settings, the translation of patient-reported outcomes from research endpoints into clinical practice is under way but incomplete. Further progress depends on standardized, surgery-relevant instruments; empirically defined thresholds for meaningful change; and routine, interpretable assessment of patient preferences and outcomes. Where these elements are in place, PRO evidence can broaden surgical consultations beyond intraocular pressure, support individualized procedure selection, and inform resource allocation. Where they are absent, as they largely remain for angle-closure disease and for populations carrying much of the global burden, patient-reported considerations may be acknowledged in principle but not consistently integrated into clinical decisions.

Methodological Challenges and Evidence Gaps

The evidence assembled above is substantial, but its capacity to guide surgical practice is limited by recurring methodological weaknesses across instruments, procedures, and populations. Four are particularly important: the heterogeneity and uneven quality of the instruments themselves; the scarcity of evidence on responsiveness and on the thresholds needed to interpret change; the narrow demographic and clinical range of the studies; and inconsistency in how patient-reported endpoints are selected and reported. These limitations are interconnected: heterogeneous instruments with uncertain responsiveness, applied to samples with limited representativeness and reported inconsistently, restrict reliable comparison of PROs across procedures.

The first problem concerns measurement. Systematic appraisals have catalogued dozens of patient-reported outcome instruments used in glaucoma, yet only a minority satisfy rigorous standards of development and validation, and many lack a clear conceptual framework or meaningful patient input.10,45 Earlier reviews reached the same conclusion, noting that most instruments met quality criteria only partially,46 and scoping work has shown that different questionnaires emphasize different constructs and perform unevenly across the disease spectrum.44 Consequently, two surgical studies reporting “quality of life” may assess different constructs with instruments of differing psychometric quality, making pooled or informal comparisons difficult.

The second problem concerns longitudinal change, which is central to evaluating the effects of surgery. Responsiveness has been studied far less than reliability or construct validity. The minimal important difference, the smallest score change considered important to patients, remains undefined for most instruments in the surgical setting; only isolated estimates exist, such as that derived for the NEI VFQ-25 within a surgical trial.3 Formal work on clinically important differences in glaucoma has more often addressed adjacent constructs such as medication adherence.115 Compounding this, generic and preference-based measures may be less sensitive to vision-specific changes, which has led to arguments against their use as the sole primary endpoint in disease-modification trials.50 Without established thresholds, it remains difficult to determine whether observed PRO changes are meaningful to patients. Interpretation is complicated further because many surgical PRO studies are unblinded or uncontrolled and may therefore be affected by regression to the mean, response shift as patients recalibrate their internal standards after surgery, and expectation effects. These factors may alter the magnitude or interpretation of observed patient-reported change and support cautious interpretation when PRO findings appear discordant with clinical measures.

The third and fourth problems concern generalizability and reporting. The majority of available studies involve patients with primary open-angle glaucoma from Western settings. Angle-closure disease and Asian populations are therefore underrepresented, and instruments and thresholds validated in one context may be used in another without appropriate recalibration.12 Follow-up is frequently short, capturing the perioperative dip and early recovery but not the durability of patient-reported benefit over the longer course of glaucoma. Reporting is inconsistent: patient-reported endpoints are often secondary, are measured with varying instruments and at varying intervals, and favorable findings may be more likely to be reported, raising concern about selective reporting.116 Together, these features limit the external validity and clinical applicability of the evidence, particularly for patients outside the populations in which the instruments were developed. Because this review was restricted to English-language articles, it may also underrepresent PRO and instrument-validation studies published in other languages, particularly in regions where angle-closure disease is common.

Addressing these challenges requires a standardized core set of patient-reported outcomes for glaucoma surgery, administered with psychometrically sound instruments and, increasingly, through adaptive systems that may facilitate routine capture; the empirical definition of minimal important differences specific to surgical populations and glaucoma subtypes; the deliberate inclusion of angle-closure disease and non-Western populations in prospective studies; and longer, prespecified follow-up with transparent, complete reporting of patient-reported endpoints regardless of direction. These priorities are not new, but their incomplete implementation continues to limit the comparability, interpretation, and clinical use of PRO evidence in glaucoma surgery.

Conclusion and Outlook

Patient-reported outcomes constitute a distinct and decision-useful class of evidence. They measure the value of glaucoma surgery in terms of patient experience: the symptom burden, functional capacity, and well-being that intraocular pressure, medication counts, and visual fields describe only indirectly. By linking instrument selection with procedure-specific evidence, determinants of postoperative outcomes, and shared decision-making, the framework presented in this review broadens the assessment of surgical success beyond ocular and pressure-based outcomes.

The practical value of this framework is fourfold: it matches instrument choice to the clinical question, supports the interpretation of patient-centered evidence across procedures, informs preoperative counseling, and, most concretely, supports individualized decisions in clinical practice. That value is greatest where conventional metrics and patient experience may diverge, as in combined cataract–angle surgery for angle-closure disease, where the relationship between patient-reported gains and the accompanying changes in pressure or acuity remains uncertain and warrants dedicated study.69

Realizing this potential requires overcoming several linked obstacles rather than any single one. Measurement remains underdeveloped in surgical settings: few instruments have been validated for responsiveness, and minimal important differences remain largely undefined. Evidence integration is limited because head-to-head patient-reported comparisons are scarce and studies may compare non-equivalent constructs. The evidence is also insufficiently representative, with angle-closure disease and Asian populations understudied relative to their global burden. Routine implementation remains limited because computerized adaptive testing and digital administration have not yet been widely integrated into surgical care.

Progress in these areas would strengthen the clinical use of PROs. An agreed core set of surgical patient-reported measures, anchored to defined thresholds, validated across glaucoma subtypes and populations, and captured efficiently in practice, would support the transition of patient-reported outcomes from research endpoints to routine tools for individualized surgical decision-making. This framework should continue to be evaluated and refined as further evidence emerges. Its most immediate clinical application is to identify the outcomes and treatment burdens most important to each patient before procedure selection and to incorporate those priorities into counseling and shared decision-making.

Funding Statement

This work was supported by the Guizhou Provincial Department of Science and Technology (Qian Ke He Cheng Guo LC [2026] Yi Ban 251; awarded to Songxin Yang) and the Qiandongnan Prefectural Science and Technology Plan Project (Qiandongnan Kehe Pingtai [2024] No. 0002-2; awarded to Kunpeng Pang). The funders had no role in the design or conduct of the review; the literature search, evidence synthesis, or interpretation of the findings; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Declaration of Generative AI and AI-Assisted Technologies in the Writing Process

During the preparation of this manuscript, the authors used ChatGPT (OpenAI; GPT-5.6 Thinking) to assist with translation, language refinement, editorial restructuring, and consistency checks of citations and terminology. The tool was not used to generate or analyze research data. All AI-assisted text was critically reviewed and revised by the authors, who verified the scientific content and references and take full responsibility for the accuracy, originality, and integrity of the final manuscript.

Abbreviations

CAT, computerized adaptive testing; COSMIN, COnsensus-based Standards for the selection of health Measurement INstruments; EQ-5D, EuroQol 5-Dimension; GAL-9, Glaucoma Activity Limitation-9; GQL-15, Glaucoma Quality of Life-15; GSS, Glaucoma Symptom Scale; HRQoL, health-related quality of life; IOP, intraocular pressure; MIGS, minimally invasive glaucoma surgery; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; PRO, patient-reported outcome; PROM, patient-reported outcome measure; QALY, quality-adjusted life-year; SF-36, 36-Item Short Form Health Survey; SF-6D, Short Form 6-Dimension; VRQoL, vision-related quality of life.

Data Sharing Statement

Data sharing is not applicable to this review because no new data were generated or analyzed. All evidence synthesized in this article is available in the cited publications.

Ethics Statement

This narrative review was based solely on published literature and involved no new human or animal participants, samples, or data. Ethical approval and informed consent were therefore not applicable.

Author Contributions

Songxin Yang and Rui Zhang contributed equally and share first authorship. Songxin Yang conceived and designed the review, conducted the literature search, synthesized and interpreted the evidence, drafted the manuscript, and acquired funding. Kunpeng Pang supervised the review, contributed to evidence interpretation, critically revised the manuscript, and acquired funding. Shunkun Pan, Rui Zhang, Xianming Ouyang, Li Li, Gang Lin, Lin Xiao, and Mei Yang contributed to evidence interpretation and critically revised the manuscript for important intellectual content. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–21. doi: 10.1016/j.ophtha.2014.05.013 [DOI] [PubMed] [Google Scholar]
  • 2.Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet. 2016;388(10052):1389–1397. doi: 10.1016/s0140-6736(16)30956-4 [DOI] [PubMed] [Google Scholar]
  • 3.Kotecha A, Feuer WJ, Barton K, Gedde SJ. Quality of life in the tube versus trabeculectomy study. Am J Ophthalmol. 2017;176:228–235. doi: 10.1016/j.ajo.2017.01.019 [DOI] [PubMed] [Google Scholar]
  • 4.Peixoto RDS, Stringa F, Cammack R, Liput J, King AJ. Emerging perspectives in quality of life after trabeculectomy surgery. Eye. 2025;39(7):1394–1399. doi: 10.1038/s41433-025-03636-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the horizon study. Ophthalmology. 2019;126(1):29–37. doi: 10.1016/j.ophtha.2018.05.012 [DOI] [PubMed] [Google Scholar]
  • 6.Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston AK. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas. 2019;10:9–24. doi: 10.2147/prom.S162802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516. doi: 10.1016/s0140-6736(18)32213-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001;108(5):887–97; discussion 898. doi: 10.1016/s0161-6420(00)00624-2 [DOI] [PubMed] [Google Scholar]
  • 9.Samuelson TW, Singh IP, Williamson BK, et al. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial. Am J Ophthalmol. 2021;229:220–229. doi: 10.1016/j.ajo.2021.03.007 [DOI] [PubMed] [Google Scholar]
  • 10.Vinokurtseva A, Quinn MP, Wai M, Leung V, Malvankar-Mehta M, Hutnik CML. Evaluating measurement properties of patient-reported outcome measures in glaucoma: a systematic review. Ophthalmol Glaucoma. 2023;6(5):541–563. doi: 10.1016/j.ogla.2023.04.007 [DOI] [PubMed] [Google Scholar]
  • 11.Medeiros FA, Gracitelli CP, Boer ER, Weinreb RN, Zangwill LM, Rosen PN. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122(2):293–301. doi: 10.1016/j.ophtha.2014.08.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Cheng HC, Guo CY, Chen YJ, et al. Patient-reported vision-related quality-of-life differences between primary angle-closure glaucoma and primary open-angle glaucoma. PLoS One. 2016;11(9):e0163123. doi: 10.1371/journal.pone.0163123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cui QN, Hays RD, Tarver ME, et al. Vision-targeted health-related quality-of-life survey for evaluating minimally invasive glaucoma surgery. Am J Ophthalmol. 2021;229:145–151. doi: 10.1016/j.ajo.2021.03.064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hays RD, Tarver ME, Eydelman M, et al. A health-related quality of life measure for patients who undergo minimally invasive glaucoma surgery. Am J Ophthalmol. 2024;266:313–320. doi: 10.1016/j.ajo.2024.05.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Singh K, Spaeth GL, Hays RD, Parke DW, Tarver ME, Eydelman M. Patient-reported outcomes for minimally invasive glaucoma surgery. Am J Ophthalmol. 2024;266:A1–a3. doi: 10.1016/j.ajo.2024.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–68. doi: 10.4137/hsi.S11093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Denniston AK, Kyte D, Calvert M, Burr JM. An introduction to patient-reported outcome measures in ophthalmic research. Eye. 2014;28(6):637–645. doi: 10.1038/eye.2014.41 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Quaranta L, Riva I, Gerardi C, Oddone F, Floriani I, Konstas AG. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33(6):959–981. doi: 10.1007/s12325-016-0333-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Che Hamzah J, Burr JM, Ramsay CR, Azuara-Blanco A, Prior M. Choosing appropriate patient-reported outcomes instrument for glaucoma research: a systematic review of vision instruments. Qual Life Res. 2011;20(7):1141–1158. doi: 10.1007/s11136-010-9831-1 [DOI] [PubMed] [Google Scholar]
  • 20.Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. doi: 10.1001/archopht.119.7.1050 [DOI] [PubMed] [Google Scholar]
  • 21.Marella M, Pesudovs K, Keeffe JE, O’connor PM, Rees G, Lamoureux EL. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci. 2010;51(6):2878–2884. doi: 10.1167/iovs.09-4494 [DOI] [PubMed] [Google Scholar]
  • 22.Pesudovs K, Gothwal VK, Wright T, Lamoureux EL. Remediating serious flaws in the National Eye Institute Visual Function Questionnaire. J Cataract Refract Surg. 2010;36(5):718–732. doi: 10.1016/j.jcrs.2009.11.019 [DOI] [PubMed] [Google Scholar]
  • 23.Nelson P, Aspinall P, Papasouliotis O, Worton B, O’brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;12(2):139–150. doi: 10.1097/00061198-200304000-00009 [DOI] [PubMed] [Google Scholar]
  • 24.Goldberg I, Clement CI, Chiang TH, et al. Assessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaire. J Glaucoma. 2009;18(1):6–12. doi: 10.1097/IJG.0b013e3181752c83 [DOI] [PubMed] [Google Scholar]
  • 25.Khadka J, Pesudovs K, McAlinden C, Vogel M, Kernt M, Hirneiss C. Reengineering the glaucoma quality of life-15 questionnaire with rasch analysis. Invest Ophthalmol Vis Sci. 2011;52(9):6971–6977. doi: 10.1167/iovs.11-7423 [DOI] [PubMed] [Google Scholar]
  • 26.Béchetoille A, Arnould B, Bron A, et al. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. Acta Ophthalmol. 2008;86(1):71–80. doi: 10.1111/j.1600-0420.2007.00999.x [DOI] [PubMed] [Google Scholar]
  • 27.Lee BL, Gutierrez P, Gordon M, et al. The glaucoma symptom scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116(7):861–866. doi: 10.1001/archopht.116.7.861 [DOI] [PubMed] [Google Scholar]
  • 28.Wren PA, Musch DC, Janz NK, Niziol LM, Guire KE, Gillespie BW. Contrasting the use of 2 vision-specific quality of life questionnaires in subjects with open-angle glaucoma. J Glaucoma. 2009;18(5):403–411. doi: 10.1097/IJG.0b013e3181879e63 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Khadka J, McAlinden C, Craig JE, Fenwick EK, Lamoureux EL, Pesudovs K. Identifying content for the glaucoma-specific item bank to measure quality-of-life parameters. J Glaucoma. 2015;24(1):12–19. doi: 10.1097/IJG.0b013e318287ac11 [DOI] [PubMed] [Google Scholar]
  • 30.Fenwick EK, Lim B, Man REK, et al. The development of a glaucoma-specific health-related quality of life item bank supporting a novel computerized adaptive testing system in Asia. J Patient Rep Outcomes. 2022;6(1):107. doi: 10.1186/s41687-022-00513-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Fenwick EK, Lim B, Man REK, et al. Measuring glaucoma quality of life in an Asian population using item banking: psychometric evaluation and computerized adaptive testing simulations. Qual Life Res. 2023;32(9):2667–2679. doi: 10.1007/s11136-023-03428-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Fenwick EK, Man REK, Lim B, et al. Efficiency, precision, validity, and reliability of GlauCAT-Asian computerized adaptive tests in measuring glaucoma-related quality of life. Transl Vis Sci Technol. 2024;13(2):6. doi: 10.1167/tvst.13.2.6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Man REK, Fenwick EK, Khadka J, et al. Psychometric evaluation of glaucoma quality of life item banks (GlauCAT) and initial assessment using computerized adaptive testing. Transl Vis Sci Technol. 2022;11(6):9. doi: 10.1167/tvst.11.6.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. [PubMed] [Google Scholar]
  • 35.Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 2012;12:43. doi: 10.1186/1471-2415-12-43 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rojananuangnit K, Sudjinda N. Utility index and patient-reported outcome measures in glaucomatous patients comparing with normal participants. Clin Ophthalmol. 2021;15:835–843. doi: 10.2147/opth.S300226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Choi S, Choi JA, Kwon JW, Park SM, Jee D. Utility values for glaucoma patients in Korea. PLoS One. 2018;13(5):e0197581. doi: 10.1371/journal.pone.0197581 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based glaucoma utility index using a discrete choice experiment. Optom Vis Sci. 2007;84(8):797–808. doi: 10.1097/OPX.0b013e3181339f30 [DOI] [PubMed] [Google Scholar]
  • 39.Goh RL, Fenwick E, Skalicky SE. The visual function questionnaire: utility index: does it measure glaucoma-related preference-based status? J Glaucoma. 2016;25(10):822–829. doi: 10.1097/ijg.0000000000000441 [DOI] [PubMed] [Google Scholar]
  • 40.Atkinson MJ, Stewart WC, Fain JM, et al. A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes. 2003;1:67. doi: 10.1186/1477-7525-1-67 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ruiz MA, Pardo A, Martinez de la Casa JM, Polo V, Esquiro J, Soto J. Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat. Ophthalmic Epidemiol. 2010;17(3):131–143. doi: 10.3109/09286581003734852 [DOI] [PubMed] [Google Scholar]
  • 42.Nordmann JP, Denis P, Vigneux M, Trudeau E, Guillemin I, Berdeaux G. Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study. BMC Health Serv Res. 2007;7:124. doi: 10.1186/1472-6963-7-124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Barker GT, Cook PF, Schmiege SJ, Kahook MY, Kammer JA, Mansberger SL. Psychometric properties of the glaucoma treatment compliance assessment tool in a multicenter trial. Am J Ophthalmol. 2015;159(6):1092–1099.e2. doi: 10.1016/j.ajo.2015.03.006 [DOI] [PubMed] [Google Scholar]
  • 44.Gazzard G, Kolko M, Iester M, Crabb DP. A scoping review of quality of life questionnaires in glaucoma patients. J Glaucoma. 2021;30(8):732–743. doi: 10.1097/ijg.0000000000001889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kashaf MS, Nagarajan N, Le JT, et al. A systematic review of patient-reported outcome instruments relevant to glaucoma. J Glaucoma. 2026;35(5):e15–e41. doi: 10.1097/ijg.0000000000002640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (Pro’s) in glaucoma: a systematic review. Eye. 2011;25(5):555–577. doi: 10.1038/eye.2011.45 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Lamoureux EL, Pallant JF, Pesudovs K, Hassell JB, Keeffe JE. The impact of vision impairment questionnaire: an evaluation of its measurement properties using Rasch analysis. Invest Ophthalmol Vis Sci. 2006;47(11):4732–4741. doi: 10.1167/iovs.06-0220 [DOI] [PubMed] [Google Scholar]
  • 48.Halawa OA, Roldan AM, Meshkin RS, et al. Factors associated with glaucoma-specific quality of life in a US glaucoma clinic in a pilot implementation of an online computerised adaptive test (GlauCAT). Br J Ophthalmol. 2023;107(8):1079–1085. doi: 10.1136/bjophthalmol-2022-321145 [DOI] [PubMed] [Google Scholar]
  • 49.van Gestel A, Webers CA, Beckers HJ, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye. 2010;24(12):1759–1769. doi: 10.1038/eye.2010.133 [DOI] [PubMed] [Google Scholar]
  • 50.Rabiolo A, Barton K, McNaught AI. Patient-reported outcome measures should not be the primary outcome in glaucoma clinical trials of disease modification. Br J Ophthalmol. 2023;107(1):3–5. doi: 10.1136/bjo-2021-320722 [DOI] [PubMed] [Google Scholar]
  • 51.Vaajanen A, Nättinen J, Aapola U, Gielen F, Uusitalo H. The effect of successful trabeculectomy on the ocular surface and tear proteomics-a prospective cohort study with 1-year follow-up. Acta Ophthalmol. 2021;99(2):160–170. doi: 10.1111/aos.14526 [DOI] [PubMed] [Google Scholar]
  • 52.Radhakrishnan S, Quigley HA, Jampel HD, et al. Outcomes of surgical bleb revision for complications of trabeculectomy. Ophthalmology. 2009;116(9):1713–1718. doi: 10.1016/j.ophtha.2009.04.003 [DOI] [PubMed] [Google Scholar]
  • 53.Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Vision-related quality of life following glaucoma filtration surgery. BMC Ophthalmol. 2017;17(1):66. doi: 10.1186/s12886-017-0466-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Klink T, Sauer J, Körber NJ, et al. Quality of life following glaucoma surgery: canaloplasty versus trabeculectomy. Clin Ophthalmol. 2015;9:7–16. doi: 10.2147/opth.S72357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J. The Ahmed Baerveldt comparison study methodology, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011;118(3):435–442. doi: 10.1016/j.ophtha.2010.07.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed versus Baerveldt study: five-year treatment outcomes. Ophthalmology. 2016;123(10):2093–2102. doi: 10.1016/j.ophtha.2016.06.035 [DOI] [PubMed] [Google Scholar]
  • 57.Bicket AK, Le JT, Azuara-Blanco A, et al. Minimally invasive glaucoma surgical techniques for open-angle glaucoma: an overview of Cochrane systematic reviews and network meta-analysis. JAMA Ophthalmol. 2021;139(9):983–989. doi: 10.1001/jamaophthalmol.2021.2351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Jones L, Maes N, Qidwai U, Ratnarajan G. Impact of minimally invasive glaucoma surgery on the ocular surface and quality of life in patients with glaucoma. Ther Adv Ophthalmol. 2023;15:25158414231152765. doi: 10.1177/25158414231152765 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Basílio AL, Moura-Coelho N, Passos I, et al. XEN(®) implant and trabeculectomy medium-term quality of life assessment and comparison of results. Int J Ophthalmol. 2018;11(12):1941–1944. doi: 10.18240/ijo.2018.12.11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Baker ND, Barnebey HS, Moster MR, et al. Ab-Externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–1721. doi: 10.1016/j.ophtha.2021.05.023 [DOI] [PubMed] [Google Scholar]
  • 61.Ahmed IIK, Rhee DJ, Jones J, et al. Three-year findings of the horizon trial: a schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–865. doi: 10.1016/j.ophtha.2020.11.004 [DOI] [PubMed] [Google Scholar]
  • 62.Pahljina C, Sarny S, Hoeflechner L, et al. Glaucoma medication and quality of life after phacoemulsification combined with a Xen Gel Stent. J Clin Med. 2022;11(12):3450. doi: 10.3390/jcm11123450 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Au Eong JTW, Low JR, Fenwick EK, et al. Effect of combined cataract and minimally invasive glaucoma surgeries on glaucoma-specific quality of life. J Clin Med. 2026;15(3):1215. doi: 10.3390/jcm15031215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Yuasa Y, Hirooka K, Okada N, et al. Vision-related quality of life following combined cataract and minimally invasive glaucoma surgery or cataract surgery alone in glaucoma patients. J Clin Med. 2023;12(9):3279. doi: 10.3390/jcm12093279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Al Habash A, Nagshbandi AA. Quality of life after combined cataract and minimally invasive glaucoma surgery in glaucoma patients. Clin Ophthalmol. 2020;14:3049–3056. doi: 10.2147/opth.S276124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Javanbakht M, Azuara-Blanco A, Burr JM, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation based on data from the EAGLE trial. BMJ Open. 2017;7(1):e013254. doi: 10.1136/bmjopen-2016-013254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Rhiu S, Hong S, Seong GJ, Kim CY. Phacoemulsification alone versus phacoemulsification combined with trabeculectomy for primary angle-closure glaucoma. Yonsei Med J. 2010;51(5):781–783. doi: 10.3349/ymj.2010.51.5.781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Zhao J, Zhang C, Pazo EE, et al. Phaco-goniosynechialysis versus phaco-trabeculectomy in patients with refractory primary angle-closure glaucoma: a comparative study. BMC Ophthalmol. 2023;23(1):144. doi: 10.1186/s12886-023-02885-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Yang S, Zhang R, Ouyang X, et al. Vision-related quality of life after phacoemulsification combined with goniosynechialysis and goniotomy in patients with primary angle-closure glaucoma and cataract. BMC Ophthalmol. 2026;26(1):212. doi: 10.1186/s12886-026-04746-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Bidiwala S, Jabarkhyl D, Bidiwala K. Outcomes of minimally invasive glaucoma surgery (MIGS) in glaucoma patients with coexisting cataract: a systematic review and meta-analysis. Cureus. 2025;17(1):e77007. doi: 10.7759/cureus.77007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Janz NK, Wren PA, Lichter PR, et al. The collaborative initial glaucoma treatment study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108(11):1954–1965. doi: 10.1016/s0161-6420(01)00874-0 [DOI] [PubMed] [Google Scholar]
  • 72.King AJ, Hudson J, Azuara-Blanco A, et al. Evaluating primary treatment for people with advanced glaucoma: five-year results of the treatment of advanced glaucoma study. Ophthalmology. 2024;131(7):759–770. doi: 10.1016/j.ophtha.2024.01.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Coleman AL, Lum FC, Gliklich RE, Velentgas P, Su Z. Quality of life and visual acuity outcomes in the registry in glaucoma outcomes research study. J Comp Eff Res. 2016;5(1):99–111. doi: 10.2217/cer.15.59 [DOI] [PubMed] [Google Scholar]
  • 74.Coleman AL, Lum FC, Velentgas P, Campion D, Su Z, Gliklich RE. RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma. J Comp Eff Res. 2016;5(1):65–78. doi: 10.2217/cer.15.56 [DOI] [PubMed] [Google Scholar]
  • 75.Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An Island-wide survey. Arch Ophthalmol. 1997;115(11):1436–1440. doi: 10.1001/archopht.1997.01100160606014 [DOI] [PubMed] [Google Scholar]
  • 76.Ma P, Liu Y, Su Y, Yang Y. Vision-related quality of life in primary angle-closure glaucoma patients with or without visual field dysfunction. J Ophthalmol. 2023;2023:9981060. doi: 10.1155/2023/9981060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Saw SM, Gazzard G, Au Eong KG, Oen F, Seah S. Utility values in Singapore Chinese adults with primary open-angle and primary angle-closure glaucoma. J Glaucoma. 2005;14(6):455–462. doi: 10.1097/01.ijg.0000185434.08051.82 [DOI] [PubMed] [Google Scholar]
  • 78.Song D, Fan S, Zhou Q, et al. Impact of primary glaucoma on health-related quality of life in China: the handan eye study. BMC Ophthalmol. 2023;23(1):377. doi: 10.1186/s12886-023-03106-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Ringsdorf L, McGwin G, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma. 2006;15(5):414–418. doi: 10.1097/01.ijg.0000212252.72207.c2 [DOI] [PubMed] [Google Scholar]
  • 80.McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143(6):1013–1023. doi: 10.1016/j.ajo.2007.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(6):941–948.e1. doi: 10.1016/j.ophtha.2007.08.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Abe RY, Diniz-Filho A, Costa VP, Gracitelli CP, Baig S, Medeiros FA. The impact of location of progressive visual field loss on longitudinal changes in quality of life of patients with glaucoma. Ophthalmology. 2016;123(3):552–557. doi: 10.1016/j.ophtha.2015.10.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Jones L, Bryan SR, Crabb DP. Gradually then suddenly? Decline in vision-related quality of life as glaucoma worsens. J Ophthalmol. 2017;2017:1621640. doi: 10.1155/2017/1621640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Peters D, Heijl A, Brenner L, Bengtsson B. Visual impairment and vision-related quality of life in the early manifest glaucoma trial after 20 years of follow-up. Acta Ophthalmol. 2015;93(8):745–752. doi: 10.1111/aos.12839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi: 10.1097/ICO.0b013e3181c325b2 [DOI] [PubMed] [Google Scholar]
  • 86.Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi: 10.1097/IJG.0b013e31815c5f4f [DOI] [PubMed] [Google Scholar]
  • 87.Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45(1):11–18. doi: 10.1097/icl.0000000000000544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–446. doi: 10.2147/opth.S29158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Stagg BC, Granger A, Guetterman TC, Hess R, Lee PP. The burden of caring for and treating glaucoma: the patient perspective. Ophthalmol Glaucoma. 2022;5(1):32–39. doi: 10.1016/j.ogla.2021.04.011 [DOI] [PubMed] [Google Scholar]
  • 90.Abe RY, Silva LNP, Silva DM, Vasconcellos JPC, Costa VP. Prevalence of depressive and anxiety disorders in patients with glaucoma: a cross-sectional study. Arq Bras Oftalmol. 2021;84(1):31–36. doi: 10.5935/0004-2749.20210006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Ajith BS, Najeeb N, John A, Anima VN. Cross sectional study of depression, anxiety and quality of life in glaucoma patients at a tertiary centre in North Kerala. Indian J Ophthalmol. 2022;70(2):546–551. doi: 10.4103/ijo.IJO_1389_21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Kong XM, Zhu WQ, Hong JX, Sun XH. Is glaucoma comprehension associated with psychological disturbance and vision-related quality of life for patients with glaucoma? A cross-sectional study. BMJ Open. 2014;4(5):e004632. doi: 10.1136/bmjopen-2013-004632 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88(11):1275–1282. doi: 10.1097/OPX.0b013e31822f4d6a [DOI] [PubMed] [Google Scholar]
  • 94.Bhorade AM, Perlmutter MS, Sabapathypillai SL, Goel M, Wilson B, Gordon MO. Rate of falls, fear of falling, and avoidance of activities at-risk for falls in older adults with glaucoma. Am J Ophthalmol. 2021;227:275–283. doi: 10.1016/j.ajo.2021.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Ramulu PY, van Landingham SW, Massof RW, Chan ES, Ferrucci L, Friedman DS. Fear of falling and visual field loss from glaucoma. Ophthalmology. 2012;119(7):1352–1358. doi: 10.1016/j.ophtha.2012.01.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.JY E, Mihailovic A, Kuo PL, et al. Characterizing the impact of fear of falling on activity and falls in older adults with glaucoma. J Am Geriatr Soc. 2020;68(8):1847–1851. doi: 10.1111/jgs.16516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Jiang ZY, Chen J, Yao J, Qian SH. Impact of binocular visual field loss on driving performance in glaucoma patients. Int J Ophthalmol. 2021;14(1):112–119. doi: 10.18240/ijo.2021.01.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Kwon M, Huisingh C, Rhodes LA, McGwin G, Wood JM, Owsley C. Association between glaucoma and At-fault motor vehicle collision involvement among older drivers: a population-based study. Ophthalmology. 2016;123(1):109–116. doi: 10.1016/j.ophtha.2015.08.043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Pujol Carreras O, Anton A, Mora C, et al. Relación entre la calidad de vida y la severidad del daño funcional en pacientes con glaucoma [Quality of life in glaucoma patients and normal subjects related to the severity of damage in each eye]. Arch Soc Esp Oftalmol. 2017;92(11):521–527. Spanish. doi: 10.1016/j.oftal.2016.10.005 [DOI] [PubMed] [Google Scholar]
  • 100.Bicket AK, Le JT, Yorkgitis C, Li T. Priorities and treatment preferences among surgery-naive patients with moderate to severe open-angle glaucoma. Ophthalmol Glaucoma. 2020;3(5):377–383. doi: 10.1016/j.ogla.2020.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Kulkarni BB, Leighton P, King AJ. Exploring patients’ expectations and preferences of glaucoma surgery outcomes to facilitate healthcare delivery and inform future glaucoma research. Br J Ophthalmol. 2019;103(12):1850–1855. doi: 10.1136/bjophthalmol-2018-313401 [DOI] [PubMed] [Google Scholar]
  • 102.Lu TC, Angell B, Dunn H, Ford B, White A, Keay L. Determining patient preferences in a glaucoma service: a discrete choice experiment. Clin Exp Ophthalmol. 2019;47(9):1146–1155. doi: 10.1111/ceo.13606 [DOI] [PubMed] [Google Scholar]
  • 103.Scheres LMJ, Hiligsmann M, van Gorcom L, Essers BAB, Beckers HJM. Eliciting preferences in glaucoma management-a systematic review of stated-preference studies. Eye. 2023;37(15):3137–3144. doi: 10.1038/s41433-023-02482-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Li T, Le JT, Hays RD, et al. Patient-reported outcomes measures and patient preferences for minimally invasive glaucoma surgical devices. Eye. 2020;34(1):205–210. doi: 10.1038/s41433-019-0676-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Sun Y, Zhou W, Zuo S, Chen C, Zhang Q, Chen Y. Factors influencing participation in shared decision-making among patients with glaucoma in China: a cross-sectional study. Patient Prefer Adherence. 2023;17:1261–1270. doi: 10.2147/ppa.S411274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Akkouche F, Bastelica P, Baudouin C, Sable S, Labbe A. Survey of patient understanding and satisfaction in glaucoma filtering surgery. Ophthalmol Glaucoma. 2025;8(6):634–642. doi: 10.1016/j.ogla.2025.06.007 [DOI] [PubMed] [Google Scholar]
  • 107.Al-Timimi Z, Sarkar S, Nand S, et al. Meaningful patient partnerships: a qualitative study of patient perspectives and shared decision-making regarding glaucoma surgery. Ophthalmol Glaucoma. 2025;8(5):440–449. doi: 10.1016/j.ogla.2025.04.006 [DOI] [PubMed] [Google Scholar]
  • 108.Robertson AO, Tadić V, Rahi JS. Attitudes, experiences, and preferences of ophthalmic professionals regarding routine use of patient-reported outcome measures in clinical practice. PLoS One. 2020;15(12):e0243563. doi: 10.1371/journal.pone.0243563 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Fraenkel A, Lee GA, Vincent SJ, Vincent RA, Bourne RRA, Shah P. Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice. BMC Ophthalmol. 2019;19(1):192. doi: 10.1186/s12886-019-1198-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Kernohan A, Homer T, Shabaninejad H, et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2022;107(10):1452–1457. doi: 10.1136/bjo-2021-320887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Healey PR, Tilden D, Jackson D, Aghajanian L. A cost-utility analysis of trabecular bypass devices versus usual care for patients with open-angle glaucoma. Pharmacoecon Open. 2022;6(3):355–365. doi: 10.1007/s41669-021-00312-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Song D, Wang L. Cost-utility analysis of treating mild stage normal tension glaucoma by surgery in China: a decision-analytic Markov model. Cost Eff Resour Alloc. 2024;22(1):13. doi: 10.1186/s12962-024-00523-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Agrawal P, Bradshaw SE. Systematic literature review of clinical and economic outcomes of micro-invasive glaucoma surgery (MIGS) in primary open-angle glaucoma. Ophthalmol Ther. 2018;7(1):49–73. doi: 10.1007/s40123-018-0131-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Cantor L, Lindfield D, Ghinelli F, et al. Systematic literature review of clinical, economic, and humanistic outcomes following minimally invasive glaucoma surgery or selective laser trabeculoplasty for the treatment of open-angle glaucoma with or without cataract extraction. Clin Ophthalmol. 2023;17:85–101. doi: 10.2147/opth.S389406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Kolli A, Daniel-Wayman S, Newman-Casey PA. The minimal clinically important difference in glaucoma medication adherence: interviews of glaucoma experts. Ophthalmic Res. 2021;64(3):524–528. doi: 10.1159/000512924 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Gutkind NE, Gedde SJ. Reporting outcomes of minimally invasive glaucoma surgery. Curr Opin Ophthalmol. 2025;36(2):140–145. doi: 10.1097/icu.0000000000001100 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable to this review because no new data were generated or analyzed. All evidence synthesized in this article is available in the cited publications.


Articles from Clinical Ophthalmology (Auckland, N.Z.) are provided here courtesy of Dove Press

RESOURCES